Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth

C Hess, V Vuong, I Hegyi, O Riesterer, J Wood, D Fabbro, C Glanzmann, S Bodis, M Pruschy, C Hess, V Vuong, I Hegyi, O Riesterer, J Wood, D Fabbro, C Glanzmann, S Bodis, M Pruschy

Abstract

The vascular endothelial growth factor (VEGF) receptor is a major target for anti-angiogenesis-based cancer treatment. Here we report the treatment effect of ionizing radiation in combination with the novel orally bioavailable VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 on endothelial cell proliferation in vitro and with tumour xenografts in vivo. Combined treatment of human umbilical vein endothelial cells with increasing doses of PTK787/ZK222584 and ionizing radiation abrogated VEGF-dependent proliferation in a dose-dependent way, but inhibition of endothelial cell proliferation was not due to apoptosis induction. In vivo, a combined treatment regimen of PTK787/ZK222584 (4 x 100 mg/kg) during 4 consecutive days in combination with ionizing radiation (4 x 3 Gy) exerted a substantial tumour growth delay for radiation-resistant p53-dysfunctional tumour xenografts derived from SW480 colon adenocarcinoma cells while each treatment modality alone had only a minimal effect on tumour size and neovascularization. SW480 tumours from animals that received a combined treatment regimen, displayed not only an extended tumour growth delay but also a significant decrease in the number of microvessels in the tumour xenograft. These results support the model of a cooperative anti-tumoral effect of angiogenesis inhibitor and irradiation and show that the orally bioavailable VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 is suitable for combination therapy with irradiation.

References

    1. J Biol Chem. 1997 Dec 19;272(51):32521-7
    1. J Cell Physiol. 1997 Nov;173(2):211-5
    1. Nature. 1998 Jul 16;394(6690):287-91
    1. Int J Cancer. 1998 Sep 11;77(6):933-6
    1. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11709-14
    1. Cancer Res. 1998 Dec 1;58(23):5411-7
    1. Cancer Res. 1998 Dec 15;58(24):5686-9
    1. Cancer Res. 1999 Jan 1;59(1):99-106
    1. Cancer Res. 1999 Jul 15;59(14):3374-8
    1. Cell. 1996 Aug 9;86(3):353-64
    1. Clin Cancer Res. 2000 Mar;6(3):971-8
    1. Cancer Res. 2000 Apr 15;60(8):2178-89
    1. Cancer Res. 2000 Sep 1;60(17):4819-24
    1. Cancer Res. 2001 Jan 1;61(1):39-44
    1. Cancer Res. 2001 Jan 15;61(2):732-8
    1. Cancer Res. 2001 Mar 15;61(6):2413-9
    1. Oncogene. 1990 Apr;5(4):519-24
    1. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579-86
    1. Nature. 1993 Apr 29;362(6423):841-4
    1. Cancer Res. 1993 Oct 1;53(19):4727-35
    1. J Biol Chem. 1994 Oct 14;269(41):25646-54
    1. Cancer Res. 1995 Nov 15;55(22):5296-301
    1. Nat Med. 1995 Jan;1(1):27-31
    1. Adv Cancer Res. 1995;67:281-316
    1. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2576-81
    1. Cancer Chemother Pharmacol. 1996;38(2):169-77
    1. J Biol Chem. 1996 Jul 26;271(30):17629-34
    1. Cancer Res. 1996 Sep 1;56(17):4032-9
    1. Oncogene. 1997 May 1;14(17):2079-89
    1. Genomics. 1997 Jun 15;42(3):483-8
    1. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8795-800

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit